Sheng, Guangying <br/><br/>
Societal implications of medical insurance coverage for imatinib as first-line treatment of chronic myeloid leukemia in China: a cost-effectiveness analysis.  [electronic resource] 

 -  Journal of medical economics  Apr 2017 
 - 371-381 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1941-837X 
<br/><br/><label>Standard No.: </label>10.1080/13696998.2016.1271336  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--administration & dosage<br/>China<br/>Cost-Benefit Analysis<br/>Decision Support Techniques<br/>Humans<br/>Imatinib Mesylate--administration & dosage<br/>Insurance Coverage--economics<br/>Insurance, Health--economics<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Markov Chains<br/>Pyrimidines--administration & dosage<br/>Quality-Adjusted Life Years